ADAPTIVE BIOTECHNOLOGIES CORPORATION Net Income (Loss) Attributable to Noncontrolling Interest
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Net Income (Loss) Attributable to Noncontrolling Interest of -$153.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$153.00K, a 828.57% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to noncontrolling interest for the quarter ending 2026-03-31 was $18.00K, a 18.18% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to noncontrolling interest for the quarter ending 2025-12-31 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$1.00K.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to noncontrolling interest for fiscal 2025 was $42.00K.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to noncontrolling interest for fiscal 2024 was -$103.00K.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to noncontrolling interest for fiscal 2023 was -$54.00K.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION net income (loss) attributable to noncontrolling interest for fiscal 2022 was -$177.00K.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$153.00K 10-Q · filed 2026-08-04 | -$135.00K 10-Q · filed 2026-08-04 | -$135.00K derived: sum of 3 quarters · filed 2026-08-04 | -$136.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $18.00K 10-Q · filed 2026-05-05 | $18.00K derived: sum of 2 quarters · filed 2026-05-05 | $17.00K derived: sum of 3 quarters · filed 2026-05-05 | $38.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.00K derived: sum of 2 quarters · filed 2026-02-26 | $20.00K derived: sum of 3 quarters · filed 2026-08-04 | $42.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.00K 10-Q · filed 2025-11-05 | $20.00K derived: sum of 2 quarters · filed 2026-08-04 | $42.00K 10-Q · filed 2025-11-05 | $17.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $21.00K 10-Q · filed 2026-08-04 | $43.00K 10-Q · filed 2026-08-04 | $18.00K derived: sum of 3 quarters · filed 2026-08-04 | -$8.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $22.00K 10-Q · filed 2026-05-05 | -$3.00K derived: sum of 2 quarters · filed 2026-05-05 | -$29.00K derived: sum of 3 quarters · filed 2026-05-05 | -$55.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$51.00K derived: sum of 2 quarters · filed 2026-02-26 | -$77.00K derived: sum of 3 quarters · filed 2026-02-26 | -$103.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | -$26.00K 10-Q · filed 2025-11-05 | -$52.00K derived: sum of 2 quarters · filed 2025-11-05 | -$78.00K 10-Q · filed 2025-11-05 | -$104.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$26.00K 10-Q · filed 2025-08-05 | -$52.00K 10-Q · filed 2025-08-05 | -$78.00K derived: sum of 3 quarters · filed 2026-02-26 | -$104.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$26.00K 10-Q · filed 2025-05-01 | -$52.00K derived: sum of 2 quarters · filed 2026-02-26 | -$78.00K derived: sum of 3 quarters · filed 2026-02-26 | -$79.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$52.00K derived: sum of 2 quarters · filed 2026-02-26 | -$53.00K derived: sum of 3 quarters · filed 2026-02-26 | -$54.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$26.00K 10-Q · filed 2024-11-07 | -$27.00K derived: sum of 2 quarters · filed 2024-11-07 | -$28.00K 10-Q · filed 2024-11-07 | -$69.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$1.00K 10-Q · filed 2024-08-01 | -$2.00K 10-Q · filed 2024-08-01 | -$43.00K derived: sum of 3 quarters · filed 2025-03-03 | -$81.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$1.00K 10-Q · filed 2024-05-07 | -$42.00K derived: sum of 2 quarters · filed 2025-03-03 | -$80.00K derived: sum of 3 quarters · filed 2025-03-03 | -$118.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$79.00K derived: sum of 2 quarters · filed 2025-03-03 | -$117.00K derived: sum of 3 quarters · filed 2025-03-03 | -$177.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | -$38.00K 10-Q · filed 2023-11-09 | -$76.00K derived: sum of 2 quarters · filed 2023-11-09 | -$136.00K 10-Q · filed 2023-11-09 | -$60.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$38.00K 10-Q · filed 2023-08-02 | -$98.00K 10-Q · filed 2023-08-02 | -$22.00K derived: sum of 3 quarters · filed 2024-02-29 | -$117.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$60.00K 10-Q · filed 2023-05-03 | $16.00K derived: sum of 2 quarters · filed 2024-02-29 | -$79.00K derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$19.00K derived: sum of 2 quarters · filed 2024-02-29 | -$19.00K 10-K · filed 2024-02-29 | |
| 2021-09-30 | -$95.00K 10-Q · filed 2022-11-03 | -$95.00K 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |